• Explore /
  • Poster
  • / A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.

A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.

Abstract Poster

Authors

Antonio Calles

Antonio Calles

Hospital General Universitario Gregorio Marañón, Madrid, Spain

Antonio Calles , Alejandro Navarro , Bernard Doger , Maria J. de Miguel , Victor Moreno , Jorge Ramón , María del Mar Galera López , Tatiana Hernandez-Guerrero , Elena Corral , Emiliano Calvo , Rosa Maria Alvarez Alvarez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04358237

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8581)

DOI

10.1200/JCO.2022.40.16_suppl.8581

Abstract #

8581

Poster Bd #

207

Abstract Disclosures

Similar Posters

First Author: Xiaojie Hu

First Author: Akihito Kawazoe

First Author: John Ebben

First Author: Sheng Li